Welcome to our dedicated page for Marimed news (Ticker: MRMD), a resource for investors and traders seeking the latest updates and insights on Marimed stock.
MariMed Inc. reports news on its multi-state cannabis operating platform, including cultivation, production, branded consumer products and retail dispensaries. Company updates commonly cover financial results, earnings-call schedules, wholesale distribution, branded product activity and retail operations tied to names such as Betty's Eddies, Bubby’s Baked, InHouse, Nature’s Heritage, Vibations and Thrive Dispensary.
Recurring developments also include capital-structure actions, preferred-stock obligations, hemp-derived THC product launches, cannabis regulatory commentary and community initiatives associated with the company's dispensary and brand portfolio.
MariMed (MRMD) reported first quarter 2026 revenue of $39.5 million, up from $37.9 million in 2025. GAAP net loss was $3.8 million, with non-GAAP net loss of $3.2 million. Non-GAAP adjusted EBITDA was $3.6 million, a margin of 9%.
The company also restructured $14.725 million of Series B preferred stock, extending the weighted average maturity to 4.6 years and removing a February 26, 2026 mandatory conversion date, which it says reduces near-term refinancing risk and supports liquidity.
MariMed (CSE: MRMD; OTCQB: MRMD) will report first quarter 2026 financial results on May 13, 2026 after market close. Management will host a conference call on May 14, 2026 at 8:00 a.m. EDT with a live webcast and on‑demand playback on the company investor relations site.
MariMed (CSE: MRMD, OTCQX: MRMD) reported fourth-quarter and full-year 2025 results: 2025 revenue $159.8M, sixth consecutive year of positive adjusted EBITDA, and wholesale sales up 11%. GAAP net loss widened to $14.5M while non-GAAP adjusted EBITDA was $16.9M. The company expanded distribution to 85% of dispensaries in core markets and completed a restructuring that extends Series B maturities to a weighted average of 4.6 years, improving near-term liquidity.
MariMed (CSE: MRMD; OTCQX: MRMD) reached a Restructuring and Exchange Agreement to extend and reprofile its $14.725 million Series B Convertible Preferred Stock obligation.
The deal removes a February 28, 2026 mandatory conversion, lengthens weighted average maturity by 4.6 years, and issues a $2.0M note (8% maturing Mar 2028), a $6.0M note (10% maturing Mar 2031), and $6.725M of Series B preferred at $0.25 per share, convertible February 2031.
MariMed (CSE: MRMD; OTCQX: MRMD) will report its fourth quarter and full year 2025 financial results on March 11, 2026 after market close. Management will host a conference call on March 12, 2026 at 8:00 a.m. EDT with a live webcast and playback available via MariMed investor relations.
MariMed (MRMD) launches a limited-edition Valentine’s seasonal: Berry In Love Betty, a strawberry-chocolate swirled fruit chew infused with full-spectrum cannabis, CBG, and horny goat weed. Available Feb 2026 at Thrive Dispensary locations and other retailers in Massachusetts, Maryland, Illinois, and Delaware.
The chew is vegan, gluten-free, dairy-free, and is positioned as a libido-enhancing seasonal offering from the Betty’s Eddies brand.
MariMed (CSE: MRMD / OTCQX: MRMD) launched a hemp-derived THC version of its Vibations hydrating drink mix in Rhode Island on Jan 22, 2026. Each stick contains 5mg THC; initial flavors are Lemon Lime (Sugar Free), Half & Half, Strawberry Lemonade, and Tropical Punch. Distribution is through licensed Rhode Island liquor stores (more than 150 approved locations) via Craft Collective Homegrown, with sales and local marketing by Modern Infusions. The company plans to evaluate early performance and may expand distribution into additional markets in H1 2026, while noting potential regulatory risk from pending federal legislation.
MariMed (CSE: MRMD / OTCQX: MRMD) issued a CEO statement on Dec. 18, 2025 responding to federal rescheduling of cannabis to Schedule III. The company called the move the "single greatest cannabis reform" and said it formally recognizes medical uses and lower abuse potential.
The statement says rescheduling will accelerate accredited medical research, expand consumer adoption as an alternative to opioids, and end the IRS Section 280E tax penalty for state-legal cannabis businesses—allowing compliant operators to be taxed like other consumer packaged goods sectors and, the company says, materially improve profitability and free cash flow.
MariMed (CSE: MRMD; OTCQX: MRMD) debuted an original song, Thrive: Anna, written by U.S. Army veteran and dispensary customer Ryan Taylor to celebrate his recovery and the welcoming environment at Thrive Dispensary in Anna, Illinois.
The company will play the song in-store across all 13 Thrive Dispensary locations in Massachusetts, Ohio, Delaware, Maryland, and Illinois, include a prerecorded introduction by a veteran team member, and make a donation to nonprofit FreedomSingsUSA in Taylor’s honor. Thrive: Anna is available for streaming on YouTube.
MariMed (CSE: MRMD / OTCQX: MRMD) launched a limited-edition winter flavor for its Betty’s Eddies cannabis fruit chews called Bundle Up Betty’s on Nov 18, 2025.
The seasonal chew combines real cranberry, orange, and warming spices and is infused with a relaxing blend of THC and CBD. Bundle Up Betty’s is available at select cannabis retailers and MariMed Thrive dispensaries in Massachusetts, Maryland, Illinois, and Delaware, and can be located via www.bettyseddies.com.